25I-NBOH Stats & Data

25I-NBOH was first synthesized in 2006 by a research team at Purdue University working under the direction of David Nichols. The compound was developed as part of ongoing investigations into serotonin receptor pharmacology, with particular interest in its potential application as a radioligand for brain imaging studies. When radiolabeled with carbon-11, 25I-NBOH has been investigated as a tool for mapping the distribution of 5-HT2A receptors in the brain using positron emission tomography (PET), where it is known by the research designation Cimbi-27. The compound had no documented history of recreational use prior to 2011, when it began appearing in online markets as a designer drug. Its emergence coincided with the broader proliferation of N-benzylphenethylamine derivatives during this period. 25I-NBOH is closely related to 25I-NBOMe—a compound that has been associated with numerous deaths and hospitalizations—and is also a known metabolite of that substance. This metabolic relationship has implications for forensic analysis, as does the compound's chemical instability: 25I-NBOH is a labile molecule that fragments into its parent compound 2C-I when subjected to routine gas chromatography methods, a characteristic that prompted the development of specialized analytical techniques for its reliable identification in forensic laboratories worldwide.

25I-NBOH is a relatively new substance, and little is known about its toxicity or interaction with other substances. It is assumed to pose similar acute health risks as 25I-NBOMe (see this section for more information). The LD50 has not yet been determined although it is likely to be potentially fatal at heavy dosages. 25I-NBOH's extreme potency means it should not be insufflated (snorted) as this method of administration has been associated with many deaths and hospitalizations with the closely related 25I-NBOMe.

Effects aggregated from 4 experience reports (4 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 4 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 8 25I-NBOH reports where another drug was taken too, 2 mention hospital, emergency services or an overdose, 0 a seizure and 0 psychosis (too few reports for percentages). In the 4 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to 25I-NBOH alone, and a mention is not always something that happened to the writer.

From 5 of 11 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 12 reports filed under 25I-NBOH

Too few reports for bars: these combinations come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• THC 5 of 12

Most common forms and preparations, as a share of the 10 reports that give one

Too few reports for bars: these forms come from 10 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Blotter / Tab 6 of 10
• Powder / Crystals 2 of 10
• Liquid 2 of 10

Redosing behavior across 10 reports